ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · IEX Real-Time Price · USD
6.18
-0.09 (-1.44%)
At close: Jul 2, 2024, 4:00 PM
6.13
-0.05 (-0.81%)
After-hours: Jul 2, 2024, 7:59 PM EDT
ImmunityBio Employees
ImmunityBio had 628 employees as of December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.
Employees
628
Change (1Y)
-97
Growth (1Y)
-13.38%
Revenue / Employee
$481
Profits / Employee
-$956,946
Market Cap
4.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 628 | -97 | -13.38% |
Dec 31, 2022 | 725 | 138 | 23.51% |
Dec 31, 2021 | 587 | 416 | 243.27% |
Dec 31, 2020 | 171 | 23 | 15.54% |
Dec 31, 2019 | 148 | -13 | -8.07% |
Dec 31, 2018 | 161 | 22 | 15.83% |
Dec 31, 2017 | 139 | 57 | 69.51% |
Dec 31, 2016 | 82 | 51 | 164.52% |
Dec 31, 2015 | 31 | 16 | 106.67% |
Dec 31, 2014 | 15 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
RadNet | 7,872 |
Option Care Health | 7,802 |
Haemonetics | 3,657 |
Alkermes | 2,100 |
Apellis Pharmaceuticals | 702 |
BridgeBio Pharma | 550 |
CRISPR Therapeutics AG | 407 |
IBRX News
- 12 days ago - ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors - Business Wire
- 25 days ago - ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update - Business Wire
- 6 weeks ago - Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast - Business Wire
- 2 months ago - ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® - Business Wire
- 2 months ago - ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types - Business Wire
- 2 months ago - ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association - Business Wire
- 2 months ago - What's going on with the ImmunityBio (IBRX) stock price? - Invezz
- 2 months ago - ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer - Business Wire